Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 54201 - 54220 out of 561067 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (L01FA03) obinutuzumab (adm: P) | Gazyva 1 g/40 mL injection, 40 mL vial | Solution for I.V. infusion 1000 mg in 40 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
n/a | RocheProductsPtyLtd |
| Australia | (L01FA03) obinutuzumab (adm: P) | Gazyva 1 g/40 mL injection, 40 mL vial | Solution for I.V. infusion 1000 mg in 40 mL, 1 pcs | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | RocheProductsPtyLtd |
| Australia | (L01FF02) pembrolizumab (adm: P) | Keytruda 100 mg/4 mL injection, 4 mL vial | Solution concentrate for I.V. infusion 100 mg in 4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms | MerckSharp&Dohme(Australia)PtyLtd |
| Australia | (L01FF02) pembrolizumab (adm: P) | Keytruda 100 mg/4 mL injection, 4 mL vial | Solution concentrate for I.V. infusion 100 mg in 4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms | MerckSharp&Dohme(Australia)PtyLtd |
| Australia | (L01FF02) pembrolizumab (adm: P) | Keytruda 100 mg/4 mL injection, 4 mL vial | Solution concentrate for I.V. infusion 100 mg in 4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms | MerckSharp&Dohme(Australia)PtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 120 mg/2.4 mL injection, 2.4 mL vial | Solution concentrate for I.V. infusion 120 mg in 2.4 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FF03) durvalumab (adm: P) | Imfinzi 500 mg/10 mL injection, 10 mL vial | Solution concentrate for I.V. infusion 500 mg in 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | AstraZenecaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
Pages
